Literature DB >> 3391631

[Rubella vaccination: antibody persistence for 14-17 years and immune status of women without and with a history of vaccination].

G Enders1, U Nickerl.   

Abstract

Out of 1045 women who had been successfully vaccinated with Cendehill vaccine, 195 were tested for rubella antibodies 13-17 years later and still 98% were seropositive with a geometric mean titer (GMT) of 2-5.4 (1:42). In 7.8% and 21.6% only borderline or low hemagglutination inhibition (HAl) titer were found. A reinfection rate of 12.2% was determined by significant titer rises and IgM antibody detection in 466 vaccinees with 3 or more blood samples during the observation period. Out of 312 successfully vaccinated girls aged 11-16 years with HPV77DE5 and RA 27/3, 130 could be retested 14 years later and all were found seropositive with a GMT of 2-5.8. Low HAl titers of 1:16 have been found in 6.2% (8 cases). The rubella immune status of 11,0978 postpubertal and pregnant women in South-West Germany was determined between 1981 and 1987. 9824 of these women had a history of vaccination and only 2.4% were seronegative in contrast to 8.2% of 101,154 women with no history of vaccination. There was a significantly higher prevalence of low levels (HAl 1:8, 1:16) of antibodies among women with a history of vaccination (19.4%) than among those without (10.6%, p less than 0.001). The effect of reinfection in pregnancy following previous vaccination on the newborn is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391631

Source DB:  PubMed          Journal:  Immun Infekt


  3 in total

1.  Humoral immune response after primary rubella virus infection and after vaccination.

Authors:  C Vauloup-Fellous; L Grangeot-Keros
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

Review 2.  Rubella vaccines: past, present and future.

Authors:  J M Best
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

3.  Congenital rubella syndrome after maternal reinfection.

Authors:  B Weber; G Enders; R Schlösser; B Wegerich; R Koenig; H Rabenau; H W Doerr
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.